Dataset Information

Proteomics of Muscle Stem Cells from diabetic mice

ABSTRACT: Proteomics was performed on 50,000 freshly isolated muscle stem cells isolated from the hindlimb muscles of 12-week-old WT and the type-1 diabetic Akita mouse model.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Muscle Stem Cell

DISEASE(S): Diabetes Mellitus

SUBMITTER: Benjamin Parker

LAB HEAD: Benjamin Parker

PROVIDER: PXD065665 | Pride | 2026-02-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	230418_Lumos_BenParker_BP-6195_GA6.raw	Raw
	230418_Lumos_BenParker_BP-6195_GA7.raw	Raw
	230418_Lumos_BenParker_BP-6195_GA8.raw	Raw
	230418_Lumos_BenParker_BP-6195_GB6.raw	Raw
	230418_Lumos_BenParker_BP-6195_GB7.raw	Raw

Items per page:

1 - 5 of 20

Publications

Intrinsic muscle stem cell dysfunction underlies functional deficits in models of type 1 diabetes.

Chung Jin D JD Trieu Jennifer J Parker Benjamin L BL Nguyen John H JH Chee Annabel A Chan Audrey S AS Jayasimhan Abhirup A Deliyanti Devy D Houweling Peter J PJ Voges Holly K HK Sourris Karly C KC Mills Richard J RJ Coughlan Melinda T MT Wilkinson-Berka Jennifer L JL Porrello Enzo R ER Lynch Gordon S GS

NPJ Regenerative medicine 20260106 1

Muscle function and regeneration are impaired in type 1 diabetes, but whether this arises directly from muscle stem cell (MuSC) dysfunction has not been addressed. Here, we utilized three-dimensional MuSC cultures (micromuscles) to demonstrate that hyperglycemia drives deficits in muscle stem cell function, leading to impaired force production in differentiated myotubes. The functional capacity of skeletal muscle was shown to decline after repeated bouts of injury in mouse models of type 1 diabe ...[more]

PMID: 41495072

Similar Datasets

Project description:Ten healthy male participants were recruited and successfully completed all preliminary testing and the two exercise bouts (Figure 1A). This randomized crossover design permitted signaling responses to workload- and duration-matched HIIT and MICT exercise to be mapped and interrogated within the same participant. Baseline whole-body anthropometric and blood glucose and lipid measurements confirmed these participants (age 25.4 ± 3.2 y; BMI 23.5 ± 1.6 kg/m2) were metabolically healthy, and maximal exercise capacity testing confirmed they were recreationally active but relatively untrained (relative V̇O2 peak 37.9 ± 5.2) in line with our recruitment strategy to maximize detection of skeletal muscle signaling responses to exercise (Figure 1B). Peak power output (Wpeak; 207.5 ± 40.3 W) was used to prescribe the relative work-matched intensities for HIIT and MICT. Lean mass from the DXA scan and resting metabolic rate (Figure 1B) were used to prescribe a standardized meal for each participant to consume prior to each exercise trial day. Following consumption of a standardized dinner meal the night before the HIIT or MICT exercise trial, blood and skeletal muscle biopsy samples were collected in the fasted state at baseline and at 5 min and 10 min of each respective exercise intensity. Participants completing the acute bout of HIIT, which consisted of 10 min total of 1-min ‘on’ intervals at 85 ± 0.1% of individual Wpeak (176 ± 34 W) and 1-min ‘off’ intervals at 50 W, displayed increased plasma lactate concentrations at 5 and 10 min of exercise relative to pre-exercise baseline (Figure 1C; P < 0.0001 and P < 0.001, respectively; main effect of time P < 0.0001) and no changes in plasma glucose (Figure 1D). In response to total work- and duration-matched acute bout of MICT at 55 ± 2% individual Wpeak (113 ± 17 W), participants displayed increased plasma lactate concentrations at 5 and 10 min of exercise versus baseline (Figure 1C; P < 0.001; main effect of time P < 0.0001) and no changes in plasma glucose (Figure 1D), with a main effect of higher plasma lactate levels in response to HIIT (Figure 1C; P < 0.05). To map the signaling networks regulated by HIIT and MICT, proteins from each skeletal muscle biopsy sample were extracted, digested to peptides with trypsin, isobarically labelled prior to phosphopeptide enrichment, fractionation and LC-MS/MS phosphoproteomic analysis (Figure 2A).